Search

Your search keyword '"Wu, Cheng-Kun"' showing total 289 results
Start Over Author "Wu, Cheng-Kun" Publication Year Range Last 50 years
Sorry, I don't understand your search. ×
289 results on '"Wu, Cheng-Kun"'

10. ChemMORT: an automatic ADMET optimization platform using deep learning and multi-objective particle swarm optimization.

Author

Yi, Jia-Cai, Yang, Zi-Yi, Zhao, Wen-Tao, Yang, Zhi-Jiang, Zhang, Xiao-Chen, Wu, Cheng-Kun, Lu, Ai-Ping, and Cao, Dong-Sheng

Subjects
DEEP learning, DRUG discovery, CONSTRAINED optimization, MOLECULAR switches, MOLECULAR structure, PARTICLE swarm optimization, DRUG development
Abstract

Drug discovery and development constitute a laborious and costly undertaking. The success of a drug hinges not only good efficacy but also acceptable absorption, distribution, metabolism, elimination, and toxicity (ADMET) properties. Overall, up to 50% of drug development failures have been contributed from undesirable ADMET profiles. As a multiple parameter objective, the optimization of the ADMET properties is extremely challenging owing to the vast chemical space and limited human expert knowledge. In this study, a freely available platform called Chemical Molecular Optimization, Representation and Translation (ChemMORT) is developed for the optimization of multiple ADMET endpoints without the loss of potency (https://cadd.nscc-tj.cn/deploy/chemmort/). ChemMORT contains three modules: Simplified Molecular Input Line Entry System (SMILES) Encoder, Descriptor Decoder and Molecular Optimizer. The SMILES Encoder can generate the molecular representation with a 512-dimensional vector, and the Descriptor Decoder is able to translate the above representation to the corresponding molecular structure with high accuracy. Based on reversible molecular representation and particle swarm optimization strategy, the Molecular Optimizer can be used to effectively optimize undesirable ADMET properties without the loss of bioactivity, which essentially accomplishes the design of inverse QSAR. The constrained multi-objective optimization of the poly (ADP-ribose) polymerase-1 inhibitor is provided as the case to explore the utility of ChemMORT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up

Author

Liu, An-Che, primary, Tai, Wei-Chen, additional, Chiu, Shao-Ming, additional, Sou, Fai-Meng, additional, Yang, Shih-Cheng, additional, Lu, Lung-Sheng, additional, Kuo, Chung-Mou, additional, Chiu, Yi-Chun, additional, Chuah, Seng-Kee, additional, Liang, Chih-Ming, additional, and Wu, Cheng-Kun, additional

Published
2023
Full Text
View/download PDF

14. Safety of cold snare polypectomy vs conventional hot polypectomy for 4 to 10 mm gastric polyps: A single‐center retrospective study

Author

Ma, Te‐Ling, Yang, Shih‐Cheng, Wu, Cheng‐Kun, Lu, Long‐Sheng, Liang, Chih‐Ming, Tai, Wei‐Chen, and Chuah, Seng‐Kee

Abstract

Endoscopic polypectomy has become standard in the management of most polyps in the gastrointestinal tract, but bleeding is the most common adverse event. Polypectomy with a cold snare (CSP) has been increasingly utilized in recent years, but further evidence is required to establish its safety of gastric polypectomy. The aim of this study was to compare intraprocedure and postprocedure adverse events in patients who underwent CSP vs conventional hot snare polypectomy (HSP) of gastric polyps. Electronic medical records and endoscopy reports of all patients who underwent gastric polypectomy at the Kaohsiung Chang Gung Memorial Hospital between January 2019 and June 2021 were retrospectively reviewed. Data on patient demographics, polyp characteristics, method of polypectomy, and adverse events were collected. A total of 193 gastric polyps removed from 111 patients were reviewed. The mean age was 58.1 years, and 74.8% were female. Of these, 142 polyps were removed from 78 patients by HSP, compared to 51 polyps removed from 33 patients by CSP. The mean polyp size was 7.9 mm in the HSP group and 7.5 mm in the CSP group (P= .306). Nine patients (11.5%) from HSP group and 5 (15.2%) from CSP group presented with immediate bleeding that were managed by endoscopic treatment (P= .755). There was no serious adverse event, such as delayed bleeding or perforation, occurred in this study. In multivariate logistic regression, only the number of polyps resected >1 was identified as independent risk factor of immediate post‐polypectomy bleeding. Therefore, the safety of CSP was non‐inferior to HSP and could be an additional option for removal of gastric polyps ≤10 mm.

Published
2024
Full Text
View/download PDF

17. The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up

Author

Liu,An-Che, Tai,Wei-Chen, Chiu,Shao-Ming, Sou,Fai-Meng, Yang,Shih-Cheng, Lu,Lung-Sheng, Kuo,Chung-Mou, Chiu,Yi-Chun, Chuah,Seng-Kee, Liang,Chih-Ming, Wu,Cheng-Kun, Liu,An-Che, Tai,Wei-Chen, Chiu,Shao-Ming, Sou,Fai-Meng, Yang,Shih-Cheng, Lu,Lung-Sheng, Kuo,Chung-Mou, Chiu,Yi-Chun, Chuah,Seng-Kee, Liang,Chih-Ming, and Wu,Cheng-Kun

Abstract

An-Che Liu,1 Wei-Chen Tai,1,2 Shao-Ming Chiu,1 Fai-Meng Sou,1 Shih-Cheng Yang,1 Lung-Sheng Lu,1 Chung-Mou Kuo,1 Yi-Chun Chiu,1,2 Seng-Kee Chuah,1,2 Chih-Ming Liang,1,2 Cheng-Kun Wu1,2 1Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2College of Medicine, Chang Gung University, Taoyuan, TaiwanCorrespondence: Cheng-Kun Wu, Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Niao Sung Dist, Kaohsiung, 833, Taiwan, Tel +886-7-731-7123 Ext 8301, Fax +886-7-732-2402, Email aasavage.tw@yahoo.com.twBackground: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the risk factors pertaining to liver abscesses following ERCP lithotomy.Methods: We conducted a retrospective case series across multiple centers to evaluate patients who developed PLA after ERCP for choledocholithiasis. Data was obtained from the Chung Gung Research Database (January 2001 to December 2018). Out of 220 enrolled patients, 195 were categorized in the endoscopic sphincterotomy (ES) group, while 25 were in the non-ES group for further analysis.Results: The non-ES group had significantly higher total bilirubin levels compared to the ES group (4.3 ± 5.8 vs 1.9 ± 2.0, p< 0.001). Abscess size, location, and distribution (single or multiple) were similar between the two groups. The most common pathogens were Klebsiella pneumoniae and Escherichia coli. Pseudomonas infection was significantly less prevalent in the ES group compared to the non-ES group (3.6% vs 16.7%, p=0.007). Patients with concurrent malignancies (HR: 9.529, 95% CI: 2.667– 34.048, p=0.001), elevated total bilirubin levels (HR: 1.246, 95% CI: 1.062– 1.461

Published
2023

22. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents

Author

Huang, Chao-Min, Hu, Tsung-Hui, Chang, Kuo-Chin, Tseng, Po-Lin, Lu, Sheng-Nan, Chen, Chien-Hung, Wang, Jing-Houng, Lee, Chuan-Mo, Tsai, Ming-Chao, Lin, Ming-Tsung, Yen, Yi-Hao, Hung, Chao-Hung, Cho, Chung-Lung, and Wu, Cheng-Kun

Published
2017
Full Text
View/download PDF

25. The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir

Author

Wu, Cheng-Kun, primary, Chen, Li-Wei, additional, Chang, Te-Sheng, additional, Tung, Shui-Yi, additional, Lin, Chun-Yen, additional, Hung, Chao-Hung, additional, Lu, Sheng-Nan, additional, Lin, Chih-Lang, additional, Chen, Chien-Hung, additional, Hsu, Chao-Wei, additional, Hu, Tsung-Hui, additional, and Sheen, I-Shyan, additional

Published
2022
Full Text
View/download PDF

26. Improving the UV-light stability of silicon heterojunction solar cells through plasmon-enhanced luminescence downshifting of YVO4:Eu3+,Bi3+nanophosphors decorated with Ag nanoparticles

Author

Wu, Cheng-Kun, Zou, Shuai, Peng, Chen-Wei, Gu, Si-Wei, Ni, Meng-Fei, Zeng, Yu-Lian, Sun, Hua, Zhang, Xiao-Hong, and Su, Xiao-Dong

Abstract

A novel composite down-shifting nanomaterial composed of YVO4:Eu3+, Bi3+nanoparticles (NPs) and Ag NPs was developed and introduced as a sunscreen on industrial SHJ solar cells to reduce the UV-induced degradation.

Published
2023
Full Text
View/download PDF

27. The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pyloriInfection in Taiwan: A Randomized Controlled Trial

Author

Tai, Wei-Chen, Yang, Shih-Cheng, Yao, Chih-Chien, Wu, Cheng-Kun, Liu, An-Che, Lee, Chen-Hsiang, Kuo, Yuan-Hung, Chuah, Seng-Kee, and Liang, Chih-Ming

Abstract

Introduction: High-dose dual therapy (HDDT) can attain acceptable eradication rates provided that the optimal doses, timing and treatment duration are applied. The existing evidence still shows inconsistent reports (&lt; 90%) on HDDT therapy except in some Asian countries. We aimed to assess and compare the efficacy of 14-day HDDT by comparing it to 14-day rabeprazole-containing hybrid therapy (HT) and to investigate the host and bacterial factors predicting the treatment outcomes of eradication therapies. Methods: In this open-label, randomized controlled trial, we recruited 243 naïve Helicobacter pylori-infected patients from September 1, 2018, to November 30, 2021. They were randomly allocated (1:1) to the HDDT group (rabeprazole 20 mg and amoxicillin 750 mg q.i.d for 14 days, n= 122) and the HT group (rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days, n= 121). Twelve patients were absent during follow-up in the HDDT group and 4 in the HT group, resulting in 110 for the HDDT group and 117 for HT group in the per protocol (PP) study. The outcome was determined by urea breath tests 8 weeks later. Results: The eradication rates for the HDDT and HT groups were 77.0% (95% confidence interval [CI]: 68.5% to 84.1%) and 94.2% (95% CI: 88.4% to 97.6%) (P&lt; 0.001) in intention-to-treat analysis; 85.5% (95% CI: 77.5% to 91.5%) and 97.4% [95% CI: 92.6% to 99.5%] (P= 0.001) in per protocol analysis. The adverse event rates were 7.3% in the HDDT group and 14.5% in the HT group (P= 0.081). The habit of coffee drinking was the dependent factor for eradication failure in the HDDT group (88.2% vs. 68.8%, P= 0.040), but had no influence in the HT group (97.9% versus 95.0%, P= 0.449) in the univariate analysis. Conclusion: This study demonstrated that 14-day rabeprazole-containing HDDT did not achieve > 90% eradication rates for first-line H. pylorieradication as 14-day rabeprazole-containing HT did. HDDT is a potentially beneficial combination, which involves only two drugs with mild adverse effects; more precise studies are urged to find answers regarding these failures.

Published
2023
Full Text
View/download PDF

29. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance

Author

Huang, Tzu-Hsin, primary, Yang, Shih-Cheng, additional, Tai, Wei-Chen, additional, Liang, Chih-Ming, additional, Kuo, Chung-Mou, additional, Yao, Chih-Chien, additional, Wu, Cheng-Kun, additional, Kuo, Yuan-Hung, additional, Chou, Yeh-Pin, additional, Lee, Chen-Hsiang, additional, Wu, Keng-Liang, additional, and Chuah, Seng-Kee, additional

Published
2021
Full Text
View/download PDF

36. A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial

Author

Tai, Wei-Chen, Liang, Chih-Ming, Bi, Kuo-Wei, Kuo, Chung-Mou, Lu, Lung-Sheng, Wu, Cheng-Kun, Yang, Shih-Cheng, Kuo, Yuan-Hung, Lee, Chen-Hsiang, Huang, Chih-Fang, Hsu, Chien-Ning, Hsu, Pin-I, Wu, Deng-Chyang, Hu, Tsung-Hui, Wu, Keng-Liang, and Chuah, Seng-Kee

Subjects
antibiotic resistance, Clinical Trial Report, dexlansoprazole MR-based concomitant therapy, lansoprazole-based concomitant therapy, Corrigendum, Helicobacter pylori eradication, strong proton-pump inhibitor
Abstract

Purpose Steadily maintaining high intra-gastric PH is the major factor for successful Helicobacter pylori (H.pylori) eradication. It is important to search for a stronger PPI. Dexlansoprazole MR is a dual delayed release formulation PPI taken once daily which is capable of maintaining longer duration of high intra-gastric PH. It is very effective in treating gastroesophageal disease but reports on H, pylori eradication is very rare. This study sought to compare dexlansoprazole MR-based concomitant treatment and lansoprazole-based concomitant treatment in H. pylori infection and to investigate the factors that affect the eradication rates. Methods Two hundred two participants with H. pylori infection were included and randomly assigned to seven days of dexlansoprazole MR-based concomitant therapy (dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily; DACM group) or a seven days of lansoprazole-based concomitant therapy (lansoprazole 30 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and metronidazole 500 mg twice daily; LACM group). The participants were asked to perform urea breath tests eight weeks later. Results The eradication rates in the DACM group were 86.1% [95% confidence interval (CI): 77.8%–92.2%] in the ITT analysis and 90.6% (95% CI: 82.9%–95.6%) in the PP analysis, respectively, as compared with 90.1% (95% CI: 82.6%–95.2%) and 92.6% (95% CI: 85.5%–96.9%) (p=0.384 and p=0.572, respectively) in the LACM group for the same analyses. The adverse event rates were 11.5% in the DACM group and 10.2% in the LACM group (p=0.779). Conclusion As a first-line H. pylori treatment regimen, dexlansoprazole MR-based concomitant therapy attained a successful eradication rate of 90%, which was non inferior to that of lansoprazole-based concomitant treatment. ClinicalTrials.gov identifier NCT03829150., Video abstract Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: https://youtu.be/AJ1z88nc4uI

Published
2019

39. Increased Risk of Pyogenic Liver Abscess after Endoscopic Sphincterotomy for Treatment of Choledocholithiasis

Author

Wu,Cheng-Kun, Hsu,Chien-Ning, Cho,Wei-Ru, Yang,Shih-Cheng, Liu,An-Che, Tai,Wei-Chen, Lee,Chen-Hsiang, Yang,Yao-Hsu, Chuah,Seng-Kee, Liang,Chih-Ming, Wu,Cheng-Kun, Hsu,Chien-Ning, Cho,Wei-Ru, Yang,Shih-Cheng, Liu,An-Che, Tai,Wei-Chen, Lee,Chen-Hsiang, Yang,Yao-Hsu, Chuah,Seng-Kee, and Liang,Chih-Ming

Abstract

Cheng-Kun Wu,1 Chien-Ning Hsu,2,3 Wei-Ru Cho,1 Shih-Cheng Yang,1 An-Che Liu,4 Wei-Chen Tai,1 Chen-Hsiang Lee,5 Yao-Hsu Yang,6– 8 Seng-Kee Chuah,1 Chih-Ming Liang1 1Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; 2Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 3School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; 4Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; 5Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan; 6Department of Traditional Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; 7Health Information and Epidemiology Laboratory of Chang Gung Memorial Hospital, Chiayi, Taiwan; 8School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanCorrespondence: Chih-Ming LiangDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123, Dabi Road, Kaohsiung, 833, TaiwanTel +886-7-731-7123, ext. 8301Fax +886-7-732-2402Email gimy54861439@gmail.comBackground and Aim: Endoscopic sphincterotomy (ES) abolished the barrier between the hepatobiliary system and duodenum and might be at risk of pyogenic liver abscess (PLA). We aimed to identify the association factors of PLA in patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) procedures for treatment of choledocholithiasis.Methods: This study was based on the Chung Gung Research Database (CGRD) between January 1, 2001 and December 31, 2018. Those who had an International Classification of Diseases, Ninth and Tenth Revision (ICD9 and ICD10) codes of choled

Published
2021

40. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Author

Hung,Kuo-Tung, Yang,Shih-Cheng, Wu,Cheng-Kun, Wang,Hsing-Ming, Yao,Chih-Chien, Liang,Chih-Ming, Tai,Wei-Chen, Wu,Keng-Liang, Kuo,Yuan-Hung, Lee,Chen-Hsiang, Chuah,Seng-Kee, Hung,Kuo-Tung, Yang,Shih-Cheng, Wu,Cheng-Kun, Wang,Hsing-Ming, Yao,Chih-Chien, Liang,Chih-Ming, Tai,Wei-Chen, Wu,Keng-Liang, Kuo,Yuan-Hung, Lee,Chen-Hsiang, and Chuah,Seng-Kee

Abstract

Kuo-Tung Hung,1 Shih-Cheng Yang,1 Cheng-Kun Wu,1,2 Hsing-Ming Wang,1 Chih-Chien Yao,1 Chih-Ming Liang,1,2 Wei-Chen Tai,1,2 Keng-Liang Wu,1,2 Yuan-Hung Kuo,1,2 Chen-Hsiang Lee,2,3 Seng-Kee Chuah1,2 1Division of Hepatogastroenterology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan; 2Chang Gung University, College of Medicine, Taoyuan, Taiwan; 3Division of Infectious Disease, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, TaiwanCorrespondence: Seng-Kee Chuah; Chih-Ming LiangDivision of Hepatogastroenterology, Chang Gung Memorial Hospital, 123, Ta-Pei Road, Niao-Sung Hsiang, Kaohsiung, 833, TaiwanTel + 886-7-7317123 ext. 8301Fax + 886-7-7322402Email chuahsk@seed.net.tw; gimy54861439@gmail.comPurpose: Non-bismuth concomitant quadruple therapy is commonly administered in Taiwan, achieving an acceptable efficacy as a first-line anti-Helicobacter pylori treatment. This study compared the eradication rates between esomeprazole- and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line anti-H. pylori treatment.Patients and Methods: This study included 206 H. pylori-infected naïve patients between July 2016 and February 2019. The patients were prescribed with either a 7-day non-bismuth containing quadruple therapy (esomeprazole, 40 mg twice daily; amoxicillin, 1 g twice daily; and metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily for 7 days [EACM group]; lansoprazole, 30 mg twice daily; amoxicillin, 1 g twice daily; metronidazole, 500 mg twice daily; and clarithromycin, 500 mg twice daily [LACM group]). Then, the patients were asked to perform urea breath tests 8 weeks later.Results: The eradication rates in the EACM group were 86.1% (95% confidence interval [CI], 77.8%– 92.2%) and 90.6% (95% CI, 82.9%– 95.6%) in the intention-to-treat (ITT) and the per-protocol (PP) analyses, respectively. Moreover, the eradication rates in the LACM group we

Published
2021

41. Risk factors of post‐endoscopic retrograde cholangiopancreatography pancreatitis among living‐donor liver transplant recipients with biliary complications

Author

Espinosa, Wendell, Chiu, Yi‐Chun, Kuo, Chung‐Mou, Liang, Chih‐Ming, Lu, Lung‐Sheng, and Wu, Cheng‐Kun

Abstract

The aim of this study is to investigate the incidence of post‐ERCP (endoscopic retrograde cholangiopancreatography) pancreatitis (PEP) among living donor liver transplant (LDLT) recipients and the risk factors that may predispose to PEP. From December 2008 to August 2015, a total of 652 adult LDLT cases were performed at the Kaohsiung Chang Gung Memorial Hospital. LDLT recipients with biliary complications undergoing ERCP treatment were recruited in this study. PEP was assessed by using established consensus criteria. Patient‐ and procedure‐related factors were collected and analyzed to investigate the association with PEP. A total of 62 (9.5%) patients developed biliary complications after LDLT and received 223 ERCP procedures. Initial ERCP treatments were successful in 58 (93.5%) patients, and 4 (6.5%) patients failing in biliary cannulation proceeded to rendezvous procedure successfully. Pancreatic duct (PD) injection had the highest incidence (23.5%) of PEP followed by a short interval between LT and ERCP (<12 weeks) (18.5%), creatinine >2 mg/dl (16.6%), initial ERCP (16.1%), precut EST (13.8%), EST (12.9%), and use of prednisone (8.9%). Univariate analysis showed that initial ERCP, precut EST, PD injection, a short interval between LT and ERCP, and use of prednisolone were associated with PEP. However, multivariate analysis revealed that only initial ERCP (OR 17.2, 95% CI 1.9–150.2) and PD injection (OR 5.4, 95% CI 1.2–24.7) were independent risk factors of PEP among LDLT recipients. LDLT recipients undergoing initial ERCP and PD injection of contrast during the procedure are at a high risk to develop PEP. Prophylactic strategies should be adopted especially in this subset of patients.

Published
2022
Full Text
View/download PDF

42. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Author

Hung, Kuo-Tung, primary, Yang, Shih-Cheng, additional, Wu, Cheng-Kun, additional, Wang, Hsing-Ming, additional, Yao, Chih-Chien, additional, Liang, Chih-Ming, additional, Tai, Wei-Chen, additional, Wu, Keng-Liang, additional, Kuo, Yuan-Hung, additional, Lee, Chen-Hsiang, additional, and Chuah, Seng-Kee, additional

Published
2021
Full Text
View/download PDF

46. Incidence of interval colorectal cancer: A tertiary hospital report

Author

Lai, Wan‐Tz, primary, Chiu, Shao‐Ming, additional, Wu, Cheng‐Kun, additional, Liang, Chih‐Ming, additional, Yang, Shih‐Cheng, additional, Yao, Chih‐Chien, additional, Kuo, Chung‐Mou, additional, Lu, Lung‐Sheng, additional, Chiu, Yi‐Chun, additional, Wu, Keng‐Liang, additional, Tai, Wei‐Chen, additional, and Chuah, Seng‐Kee, additional

Published
2020
Full Text
View/download PDF

49. Single‐stage retrograde endoscopic common bile duct stone removal might be sufficient in moderate acute cholangitis with a stone size ≤12 mm: A retrospective cohort study with propensity score matching

Author

Hung, Kuo‐Tung, primary, Kuo, Chung‐Mou, additional, Tsai, Cheng‐En, additional, Chiu, Yi‐Chun, additional, Lu, Lung‐Sheng, additional, Wu, Cheng‐Kun, additional, Sou, Fai‐Meng, additional, Huang, Pao‐Yuan, additional, Tai, Wei‐Chen, additional, Kuo, Chung‐Huang, additional, Liang, Chih‐Ming, additional, and Chuah, Seng‐Kee, additional

Published
2020
Full Text
View/download PDF

50. Incidence and risk factors of colonoscopic post‐polypectomy bleeding and perforation in patients with end‐stage renal disease

Author

Yang, Shih‐Cheng, primary, Wu, Cheng‐Kun, additional, Tai, Wei‐Chen, additional, Liang, Chih‐Ming, additional, Li, Yu‐Chi, additional, Yeh, Wen‐Shuo, additional, Lee, Chen‐Hsiang, additional, Yang, Yao‐Hsu, additional, Tsai, Tzu‐Hsien, additional, Hsu, Chien‐Ning, additional, and Chuah, Seng‐Kee, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results